Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles

Immunogenicity and Safety of a Multicomponent Meningococcal Serogroup B Vaccine and a Quadrivalent Meningococcal CRM197Conjugate Vaccine against Serogroups A, C, W-135, and Y in Adults Who Are at Increased Risk for Occupational Exposure to Meningococcal Isolates

(2010) Alan Kimura et al.   Clinical and Vaccine Immunology

Characterization of fHbp, nhba (gna2132), nadA, porA, and Sequence Type in Group B Meningococcal Case Isolates Collected in England and Wales during January 2008 and Potential Coverage of an Investigational Group B Meningococcal Vaccine

(2010) J. Lucidarme et al.   Clinical and Vaccine Immunology

Multicenter, Open‐Label, Randomized Phase II Controlled Trial of an Investigational Recombinant Meningococcal Serogroup B Vaccine With and Without Outer Membrane Vesicles, Administered in Infancy

(2010) Jamie Findlow et al.   CLINICAL INFECTIOUS DISEASES

Genetic shifts ofNeisseria meningitidisserogroup B antigens and the quest for a broadly cross-protective vaccine

(2010) Xilian Bai et al.   Expert Review of Vaccines

Immunogenicity and Reactogenicity of a 13-Valent-pneumococcal Conjugate Vaccine Administered at 2, 4, and 12 Months of Age

(2010) Matthew D. Snape et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans

(2010) Davide Serruto et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines

(2010) J. Donnelly et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus

(2010) Marzia M. Giuliani et al.   VACCINE

Influence of sequence variability on bactericidal activity sera induced by Factor H binding protein variant 1.1

(2010) Brunella Brunelli et al.   VACCINE

Phase I Safety and Immunogenicity Study of a Candidate Meningococcal Disease Vaccine Based on Neisseria lactamica Outer Membrane Vesicles

(2009) A. R. Gorringe et al.   Clinical and Vaccine Immunology

Genetically Modified L3,7 and L2 Lipooligosaccharides from Neisseria meningitidis Serogroup B Confer a Broad Cross-Bactericidal Response

(2009) V. Weynants et al.   INFECTION AND IMMUNITY

Characterization of fHbp, nhba (gna2132), nadA, porA, Sequence Type (ST), and Genomic Presence of IS1301 in Group B Meningococcal ST269 Clonal Complex Isolates from England and Wales

(2009) J. Lucidarme et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Sequence Diversity of the Factor H Binding Protein Vaccine Candidate in Epidemiologically Relevant Strains of Serogroup BNeisseria meningitidis

(2009) Ellen Murphy et al.   JOURNAL OF INFECTIOUS DISEASES

Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates

(2009) Muriel C. Schneider et al.   NATURE

Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus

(2009) Stefania Bambini et al.   VACCINE

Prevalence and sequence variations of the genes encoding the five antigens included in the novel 5CVMB vaccine covering group B meningococcal disease

(2009) Susanne Jacobsson et al.   VACCINE

Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease

(2009) Carl E. Frasch et al.   VACCINE

Global epidemiology of meningococcal disease

(2009) Lee H. Harrison et al.   VACCINE

Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates

(2009) Rolando Pajon et al.   VACCINE

A Novel Phase Variation Mechanism in the Meningococcus Driven by a Ligand-Responsive Repressor and Differential Spacing of Distal Promoter Elements

(2009) Matteo M. E. Metruccio et al.   PLoS Pathogens

CPG 7909 Adjuvant plus Hepatitis B Virus Vaccination in HIV‐Infected Adults Achieves Long‐Term Seroprotection for Up to 5 Years

(2008) C. L. Cooper et al.   CLINICAL INFECTIOUS DISEASES

Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years

(2008) Y. Galloway et al.   INTERNATIONAL JOURNAL OF EPIDEMIOLOGY

Impact of Meningococcal Serogroup C Conjugate Vaccines on Carriage and Herd Immunity

(2008) Martin C. J. Maiden et al.   JOURNAL OF INFECTIOUS DISEASES